Shares of Denali Therapeutics (DNLI) dropped significantly in after-hours trading following the news that its Phase 2 study of oditrasertib for multiple sclerosis was discontinued due to failure to meet primary and secondary endpoints. The company is expected to provide further details on the study’s termination during its upcoming earnings call.